LUGANO, Switzerland – The ESMO Asia Congress 2022 will be held in person in Singapore and virtually between 2-4 December 2022.
The programme will put special emphasis on the presentation and discussion of the latest scientific and clinical advances across the entire field of oncology, of relevance especially for the Asia-Pacific region.
- Results of novel trials from the Asia-Pacific region:
- Efficacy and safety of the randomised, double-blind, multicentre phase 3 study ASTRUM-007 in oesophageal squamous cell carcinoma, using the Chinese manufactured immunotherapy drug serplulimab (Abstract 69O)
- Preliminary results of a phase 3 multicenter randomised controlled trial in locoregionally advanced nasopharyngeal carcinoma, the most common cancer type in Asia (Abstract 221O)
- Results from prospective, randomised, controlled, multicenter clinical trial RECUT, an academic effort looking at the use of preoperative chemotherapy prior to primary tumour resection for colorectal cancer (Abstract 43O)
- Results in the Asian populations of major global trials:
- Results from the randomised, double-blind, multinational phase III study LASER301 in non-small cell lung cancer (Abstract LBA7)
- Longer-term follow-up from the Asian subgroup of the JAVELIN Bladder 100 trial in advanced urothelial carcinoma (Abstract 137MO)
- 5-year update from phase 3 ALESIA study in non-small cell lung cancer (Abstract LBA11)
- Lung cancer in non-smokers: proteogenomics in East Asia, challenges in individualising treatment options and implications for screening
(Educational session “Lung cancer in non-smokers” and Keynote lecture “Established lung cancer screening for non-smokers”)
- Affordability and availability of currently available and upcoming anti-cancer agents in Asia
(Mini oral sessions breast cancer, haematological malignancies)
- Survival benefits and improved quality of life for Head & Neck patients, with a focus on the differences between EU and Asia
(Proffered paper session head and neck cancer - 224O)
- Impact of race and ethnicity on prostate cancer and the importance of including minorities when studying the genomic characterisation
(Mini oral session genitourinary tumours - 162MO)
- Novel therapeutic strategies in urological cancers with a focus on optimising the use of novel hormonal agents in advanced prostate cancer
(Proffered paper and mini oral sessions genitourinary tumours)
- Predominant issues for Asian breast cancer patients and recommendations for tailored surveillance strategies (Mini oral session breast cancer)
- Perspectives from Asian countries on gender balance in oncology
(Special session “Gender balance in oncology: Perspective from Asia – a special session with ESMO Women for Oncology”)
- Changes in the needs of survivors and patients' families following the social changes associated with the Covid-19 pandemic, and how palliative and supportive care are trying to respond to these social changes
(Mini oral session supportive and palliative care and educational session “COVID-19 lessons from experiences in supportive and palliative care”)
The accepted abstracts and any press release prepared by ESMO will be made available under embargo to accredited media representatives on 25 November.
ESMO welcomes media interested in reporting from the ESMO events and on cancer issues. The ESMO Press Office will consider only media accreditation requests received through the official ESMO media registration form. Accreditation in advance is strongly recommended.
In addition to the embargoed material, accredited media representatives will have access to all congress sessions (in person and through the congress virtual platform), posters and e-posters, exhibition, industry satellite symposia, and will be able to watch the congress webcasts.
ESMO Press Office
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO Asia Congress 2022
Official Congress hashtag: #ESMOAsia22